ArticleCommunications medicine2026
Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAlthough the emergency phase of the COVID-19 pandemic is over, attention has remained focused towards ongoing vaccination programs and the protection of high risk populations. The DS-5670 lipid nanoparticle-mRNA vaccine platform contains SARS-CoV-2 spike protein receptor-binding domain (RBD)-derived antigen(s). We conducted studies to provide supporting evidence for DS-5670 as a source of seasonal boosters using RBD antigens from variant strains and different valency compositions.
methodsRandomized, active-comparator, non-inferiority studies evaluated monovalent DS-5670a (original strain RBD; Study 146 in 4518 adults ≥18 years) or bivalent DS-5670a/b (original and omicron BA.4-5 RBDs; Study 212 in 701 participants ≥12 years) as boosters. Primary efficacy endpoints were the GMFR in serum neutralization titers against SARS-CoV-2 (original strain) at 4 weeks (day 29) after study drug administration (Study 146), and the GMT and seroresponse rate of anti-SARS-CoV-2 (omicron BA.5 strain) serum neutralization titers on day 29 (Study 212).
resultsWe show that both studies exceed non-inferiority margins. In Study 146, day 29 adjusted geometric mean fold-rise ratios for DS-5670a are 1.464 (97.5% confidence intervals 1.112, 1.927) vs BNT162b2 and 1.772 (1.335, 2.353) vs mRNA-1273. In Study 212, day 29 adjusted geometric mean titer ratio (DS-5670a/b vs bivalent BNT162b2) is 1.712 (95% confidence intervals, 1.509, 1.944); the between-group difference in seroresponse is 21.4% (13.8, 28.6). Both DS-5670 compositions are effective against symptomatic COVID-19, with broad neutralization activity across omicron sub-lineages. No serious adverse events are associated with DS-5670 in either study.
conclusionsThis platform can be utilized to produce new vaccines against future SARS-CoV-2 variants.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.